JP2016512819A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512819A5
JP2016512819A5 JP2016500903A JP2016500903A JP2016512819A5 JP 2016512819 A5 JP2016512819 A5 JP 2016512819A5 JP 2016500903 A JP2016500903 A JP 2016500903A JP 2016500903 A JP2016500903 A JP 2016500903A JP 2016512819 A5 JP2016512819 A5 JP 2016512819A5
Authority
JP
Japan
Prior art keywords
formulation
azithromycin
acid
formulation according
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500903A
Other languages
English (en)
Japanese (ja)
Other versions
JP6589099B2 (ja
JP2016512819A (ja
Filing date
Publication date
Priority claimed from US13/843,267 external-priority patent/US9044508B2/en
Application filed filed Critical
Publication of JP2016512819A publication Critical patent/JP2016512819A/ja
Publication of JP2016512819A5 publication Critical patent/JP2016512819A5/ja
Application granted granted Critical
Publication of JP6589099B2 publication Critical patent/JP6589099B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500903A 2013-03-15 2014-03-07 濃縮水性アザライド製剤 Active JP6589099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,267 2013-03-15
US13/843,267 US9044508B2 (en) 2013-03-15 2013-03-15 Concentrated aqueous azalide formulations
PCT/US2014/022084 WO2014150067A1 (en) 2013-03-15 2014-03-07 Concentrated aqueous azalide formulations

Publications (3)

Publication Number Publication Date
JP2016512819A JP2016512819A (ja) 2016-05-09
JP2016512819A5 true JP2016512819A5 (cg-RX-API-DMAC10.html) 2017-04-06
JP6589099B2 JP6589099B2 (ja) 2019-10-16

Family

ID=51529897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500903A Active JP6589099B2 (ja) 2013-03-15 2014-03-07 濃縮水性アザライド製剤

Country Status (7)

Country Link
US (1) US9044508B2 (cg-RX-API-DMAC10.html)
EP (1) EP2968383B1 (cg-RX-API-DMAC10.html)
JP (1) JP6589099B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150130319A (cg-RX-API-DMAC10.html)
CN (1) CN105073123B (cg-RX-API-DMAC10.html)
CA (1) CA2903759C (cg-RX-API-DMAC10.html)
WO (1) WO2014150067A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692469C1 (ru) * 2018-06-25 2019-06-25 ООО "Новые Антибиотики" Лекарственное средство для лечения и предупреждения возникновения осложнений, связанных с химиотерапией и рентгенотерапией, а также состояний, связанных с повышенной проницаемостью кишки
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US12521411B2 (en) 2024-05-06 2026-01-13 Baxter International Inc. Azithromycin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798033A (en) 1954-01-07 1957-07-02 Allied Chem & Dye Corp Separation of methanol from aqueous formaldehyde
US4192827A (en) 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
ATE243703T1 (de) * 2000-01-27 2003-07-15 Pfizer Prod Inc Antibiotische azalid-zusammensetzungen
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
US8501800B2 (en) * 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles

Similar Documents

Publication Publication Date Title
JP2012107046A5 (cg-RX-API-DMAC10.html)
AR099756A1 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso, composición farmacéutica
JP2012092139A5 (cg-RX-API-DMAC10.html)
JP2010150292A5 (cg-RX-API-DMAC10.html)
BRPI0711380A2 (pt) hidrogéis de misturas de polissacarídeos para engenharia de tecido e como veículos de compostos ativos
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
JP2015516240A5 (cg-RX-API-DMAC10.html)
JP2014518275A5 (cg-RX-API-DMAC10.html)
EP2892517A1 (en) Antimicrobial composition
NO20083722L (no) Immunogen sammensetning
AR049113A1 (es) Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprost
WO2016193810A8 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
JP2017533186A5 (cg-RX-API-DMAC10.html)
JP2012532115A5 (cg-RX-API-DMAC10.html)
RU2018112239A (ru) Фармацевтическая композиция на основе трамадола для офтальмологического применения
BR112017022821A2 (pt) solução aquosa homogênea de quitosana injetável apresentando um ph próximo do ph fisiológico
JP2019142974A5 (cg-RX-API-DMAC10.html)
ES2947518T3 (es) Proceso para producir chitosan bajo en endotoxinas
CN107496439A (zh) 一种高效安全的壳聚糖衍生物基消毒液及其制备方法
KR20170080666A (ko) 안과용 수성 조성물
FI2765988T3 (fi) Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus
CN104337756A (zh) 一种壳聚糖妇科凝胶及其制备方法
JP2013529632A5 (cg-RX-API-DMAC10.html)
CN105232449A (zh) 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
JP5740906B2 (ja) 眼科用剤